Lexeo Therapeutics, Inc.’s LXEO share price has surged by 17.04%, which has investors questioning if this is right time to ...

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...

Discover 9 promising small molecule drug discovery companies that recently raised funding for their potentially breakthrough ...

Q1 2025 Earnings Call Transcript May 15, 2025 Operator: Good morning, and welcome to Mersana Therapeutics First Quarter 2025 ...

Journey Medical Corporation (NASDAQ: DERM) Q1 2025 Earnings Call Transcript May 14, 2025 Journey Medical Corporation beats ...

Cash expected to fund operations into the second half of 2026Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma ...

Operator: Good afternoon, and welcome to Oncolytics Biotech First Quarter Conference Call. All participants are in a listen-only mode.

Inebilizumab was especially effective for patients with pancreatic and biliary immunoglobulin G4-related disease, with ...

In June 2024, Nuance Pharma's global partner Verona Pharma plc (Nasdaq: VRNA), announced the US Food and Drug Administration ("FDA") approved Ohtuvayre™ (ensifentrine) for the maintenance treatment of ...

Robust.AI, a leader in AI-driven warehouse automation, today announced a strategic manufacturing partnership with Hon Hai Technology Group ("Foxconn") (TWSE:2317), the world's largest electronics ...

Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the ...

In the Phase II LUMINOSITY study, Emrelis (telisotuzumab vedotin-tllv), a first-in-class c-Met-directed antibody-drug ...